Biotechnology - Licensing, Respiratory and Pulmonary


Popular Filters

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

AstraZeneca licensing deal validates Synairgen’s approach, say analysts


Anglo-Swedish drug major AstraZeneca’s recent $230 million deal with British respiratory drug development…

AsthmaAstraZenecaBiotechnologyInterferonLicensingRespiratory and PulmonaryRespiratory therapySNG001SynairgenUK

Aslan Pharma signs agreement with CSL to develop novel therapy for asthma


Singapore-based Aslan Pharmaceuticals has signed a global license agreement to develop an anti-interleukin…

ASLAN PharmaceuticalsBiotechnologyCSL LimitedCSL334LicensingRespiratory and Pulmonary

Cytos Biotech to wind down key operational activities


Switzerland-based Cytos Biotechnology has entered into agreements with major creditors resulting in a…

BiotechnologyCYT003Cytos BiotechnologyFinancialLicensingRespiratory and Pulmonary

Whooping cough vaccine agreement signed by ILiAD


US biotech company ILiAD Biotechnologies has signed scientific collaboration and worldwide license agreements…

BiotechnologyFranceILiAD BiotechnologiesLicensingResearchRespiratory and PulmonaryUSA

Stallergenes and DBV Technologies partner on developing novel respiratory allergies treatments


French biotech firms DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the treatment…

BiotechnologyDBV TechnologiesLicensingResearchRespiratory and PulmonaryStallergenes

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs


US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Infinity amends PI3K-delta, gamma accord with Millennium


US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Ablynx extends Nanobody deal with Boehringer


Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

US Rx cough/cold deal boosts Vernalis


UK biotech firm Vernalis (LSE: VER) saw its share price rocket 28% to 25.2 pence last Friday, when the…

BiotechnologyLicensingNorth AmericaResearchRespiratory and PulmonaryTris PharmaVernalis

Back to top